Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF JUNE 20, 2004 FBO #0937
SOURCES SOUGHT

68 -- DIG-ELISA Kits for the Identification of C. botulinum Toxins A, B, E, and F

Notice Date
6/18/2004
 
Notice Type
Sources Sought
 
NAICS
325413 — In-Vitro Diagnostic Substance Manufacturing
 
Contracting Office
Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, GA, 30341-4146
 
ZIP Code
30341-4146
 
Solicitation Number
Reference-Number-200-2004-07569
 
Response Due
7/2/2004
 
Archive Date
7/17/2004
 
Point of Contact
Teri Routh-Murphy, Contract Specialist, Phone 770-488-2648, Fax 770-488-2777, - Jeffrey Napier, Contract Specialist, Phone 770-488-2861, Fax 770-488-2671,
 
E-Mail Address
tnr3@cdc.gov, jkn7@cdc.gov
 
Description
CDC intends to issue a sole source modification to Roche Diagnostics Corporation under contract 200-2004-07569. The purpose of the modification is to procure DIG- ELISA kits that can detect C. botulinum toxin types A, B, E, and F. Two important components of the kits are (1) SA coated plates and anti DIG POD, Fab fragments: The streptavidin-coated microtiter plates resulting in high binding capacity, high coating homogeneity, high intra and inter-assay reproducibility, and no leaching; and (2) Anti-DIG-HRP, Fab fragments specifically recognize digoxigenin with extremely high binding affinity and no cross-reactivity. One kit is defined as one antibody coated 96-well strip microtiter plate used to detect one toxin type, supplied with adequate reagents to perform 96 ELISA reactions. The microtiter plate will consist of eight 12-well strips coated with one specific antibody type, either A, B, E, or F. Each 12 well strip will be identified to indicate capture antibody type. Each microtiter plate will be coated, blocked, and vapor barrier packaged. The contractor must be able to supply all reagents required for testing, i.e. Anti-digoxigenin, Fab fragment conjugated to horseradish peroxidase and TMB. In addition the contractor must have least 10 years experience in the labeling and coating manufacturing and production processes. The period of performance will commence July 6, 2004 through October 15, 2004. The point of contact for this procurement is Teri Routh-Murphy, Centers for Disease Control and Prevention, 2920 Brandywine Road, MS-K14, Room 3718, Atlanta, GA 30341 or email: tnr3@cdc. No telephone calls will be accepted. Numbered Note 22.
 
Place of Performance
Address: 9115 Hague Road, Indianapolis, IN 46250
Zip Code: 46250
Country: US
 
Record
SN00606055-W 20040620/040618211746 (fbodaily.com)
 
Source
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.